Viewing nowSubaroadi Tablet 10mg (Rosuvastatin Calcium (Unmicronized))
Rosuvastatin Calcium Micronized 10.4mg
Orally disintegrating Tablet · Prescription medication
BC World Pharma Co., Ltd.

MFDS item code 202107781 · Approved 2021.12.02 · Insurance code 653103700
Improvement of dyslipidemia, inhibition of the progression of atherosclerosis, and reduction of cardiovascular risk
This medication is used as an adjunct for patients with primary hypercholesterolemia and mixed dyslipidemia when dietary and exercise control are insufficient. It particularly helps lower blood LDL cholesterol levels in patients with familial hypercholesterolemia, thereby delaying the progression of atherosclerosis. It is also used for pediatric patients aged 10 to 17 years whose hypercholesterolemia is not controlled by diet alone, as well as in the treatment of patients with primary dysbetalipoproteinemia. This medication is effective in lowering the risk of cardiovascular diseases and reducing the risk of stroke, myocardial infarction, and arterial revascularization. In summary, this medication is used to improve various diseases related to hypercholesterolemia and to reduce cardiovascular risk.
This medicine is an orally disintegrating tablet. Place it on the tongue, allow it to dissolve, and take it without water. 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 mg daily. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of this medicine at a dose of 40 mg is contraindicated in some of these patients.
2. Pediatric patients with heterozygous familial hypercholesterolemia (aged 10 to 17 years): The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses greater than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Children under 10 years: Safety and efficacy have not been established.
This medication should not be used in certain patients. For example, individuals with allergies to its ingredients, active liver disease, muscle disorders, severe renal impairment, women who are pregnant or breastfeeding, and women of childbearing age who do not use adequate contraception should not be administered this medication. Additionally, in cases where there is susceptibility to myopathy or rhabdomyolysis, particularly high doses (40mg) are prohibited. Such conditions include moderate or severe renal impairment, hypothyroidism, family or personal history of muscle disorders, alcoholism, and concomitant use of certain medications. When administering this medication, liver function and muscle status should be periodically evaluated. If there is an abnormal elevation in liver enzyme levels or symptoms such as muscle pain, muscle weakness, or muscle cramps, the healthcare provider should be notified immediately. In particular, if the blood creatine kinase (CK) level is significantly elevated, administration should be stopped. This medication should be used with caution in patients who consume large amounts of alcohol or have a history of liver disease, and those with hypothyroidism or nephrotic syndrome should be treated for those conditions before starting this treatment. Additionally, there may be interactions when used with other medications, so it is essential to inform the healthcare provider of any current medications. Co-administration with some drugs may increase the blood concentration of this medication, raising the risk of muscle-related side effects. Women who are pregnant or breastfeeding should not use this medication, and women of childbearing potential should use adequate contraception. This medication may pose a risk to the fetus, and there may be adverse effects for the baby if breastfeeding. In the case of overdose, there are no specific antidotes, so immediate medical attention should be sought for symptom-specific treatment, and liver function and muscle status should be checked periodically. Finally, while this medication does not significantly affect the ability to drive or operate machinery, dizziness and other symptoms may occur, so caution should be exercised.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is recommended to maintain storage temperatures between 1 to 30 degrees Celsius.
White to pale yellow round oral disintegrating tablet
30 tablets/box [10 tablets/PTP × 3], 10 tablets/box [10 tablets/PTP × 1]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowRosuvastatin Calcium Micronized 10.4mg
Orally disintegrating Tablet · Prescription medication
BC World Pharma Co., Ltd.

Rosuvastatin Calcium Micronized 20.8mg
Tablet · Prescription medication
Daewoong Pharmaceutical Co., Ltd.

Rosuvastatin Calcium Micronized 5.2mg
Tablet · Prescription medication
Daiwoo Pharmaceutical Co., Ltd.

Rosuvastatin Calcium Micronized 10.4mg
Tablet · Prescription medication
Daewoong Pharmaceutical Co., Ltd.

Rosuvastatin Calcium Micronized 10.4mg
Tablet · Prescription medication
Hanin Pharmaceutical Co., Ltd.

Rosuvastatin Calcium Micronized 10.4mg
Tablet · Prescription medication
Myungjin Pharmaceutical Co., Ltd.

Rosuvastatin Calcium Micronized 5.2mg
Tablet · Prescription medication
Teragen Itex Co., Ltd.

Rosuvastatin Calcium Micronized 10.4mg
Tablet · Prescription medication
Teragen Etex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.